Pub Date : 2025-10-24eCollection Date: 2025-01-01DOI: 10.21037/tbcr-25-16
Janhavi Venkataraman, Kefah Mokbel
{"title":"Methodological considerations in predicting axillary residual disease using imaging features.","authors":"Janhavi Venkataraman, Kefah Mokbel","doi":"10.21037/tbcr-25-16","DOIUrl":"10.21037/tbcr-25-16","url":null,"abstract":"","PeriodicalId":101427,"journal":{"name":"Translational breast cancer research : a journal focusing on translational research in breast cancer","volume":"6 ","pages":"40"},"PeriodicalIF":1.4,"publicationDate":"2025-10-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12593982/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145484416","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-10-24eCollection Date: 2025-01-01DOI: 10.21037/tbcr-25-18
Bin-Bin Cong, Xiao-Shan Cao, Yong-Sheng Wang, Wen G Jiang, Lin Ye
Background: Lymph node metastasis is an important predictive factor for the prognosis of breast cancer. Bone morphogenetic protein (BMP) and hepatocyte growth factor (HGF), and its receptor MET, are involved in metastasis. However, their predictive potential in the prediction of lymph node metastasis from breast cancer has not been evaluated to date. The aim of this study is to evaluate the implication of HGF and BMPs in breast cancer lymphatic metastasis.
Methods: The association between the ligands and receptors of BMP, the regulators of HGF, and the modulators of MET were detected in Cardiff clinical breast cancer cohort and The Cancer Genome Atlas (TCGA) breast cancer ribonucleic acid (RNA) sequencing database. Predictive model of HGF and BMPs for nodal metastasis was evaluated by binary logistic regression and receiver operating characteristic (ROC) curve.
Results: BMP-2 expression was upregulated but BMP-7 and matriptase-2 expression were downregulated in patients with nodal metastases. MET, matriptase-1, BMP-15, HAI-1, and matriptase-2 were correlated with the lymphangiogenesis markers. Lymphatic metastasis was positively with MET, matriptase-1 and BMP-15 but was negatively with matriptase-2, BMP-3, and HAI-1. ROC curve analysis showed the six factors with nodal status had a significant area under the curve values (0.657, P=0.001). The integrated signature could effectively predict lymph nodes involvement (P=0.006, hazard ratio =2.929).
Conclusions: The aberrant expression of HGF/MET and BMPs is related to lymphatic metastasis in breast cancer. Integrated expression level of MET/BMP-15/matriptase-1 and the inversed HAI-1/BMP-3/matriptase-2 establishes a predictive model for lymph node involvement.
背景：淋巴结转移是乳腺癌预后的重要预测因素。骨形态发生蛋白（BMP）和肝细胞生长因子（HGF）及其受体MET参与转移。然而，迄今为止，它们在预测乳腺癌淋巴结转移方面的预测潜力尚未得到评估。本研究的目的是评估HGF和bmp在乳腺癌淋巴转移中的意义。方法：在Cardiff临床乳腺癌队列和The cancer Genome Atlas （TCGA）乳腺癌核糖核酸（RNA）测序数据库中检测BMP配体与受体、HGF调节剂和MET调节剂之间的关联。采用二元logistic回归和受试者工作特征（ROC）曲线评价HGF和bmp对淋巴结转移的预测模型。结果：淋巴结转移患者中BMP-2表达上调，BMP-7和基质酶-2表达下调。MET、基质酶-1、BMP-15、HAI-1和基质酶-2与淋巴管生成标志物相关。淋巴转移与MET、基质蛋白酶-1、BMP-15呈阳性，与基质蛋白酶-2、BMP-3、HAI-1呈阴性。ROC曲线分析显示，具有节点状态的6个因素曲线值下面积显著（0.657，P=0.001）。综合特征能有效预测淋巴结受累（P=0.006，风险比=2.929）。结论：HGF/MET和bmp的异常表达与乳腺癌淋巴转移有关。MET/BMP-15/ matripase -1和HAI-1/BMP-3/ matripase -2的综合表达水平建立了淋巴结受累的预测模型。
{"title":"Predictive potential of hepatocyte growth factor and bone morphogenetic proteins in lymphatic metastasis of breast cancer.","authors":"Bin-Bin Cong, Xiao-Shan Cao, Yong-Sheng Wang, Wen G Jiang, Lin Ye","doi":"10.21037/tbcr-25-18","DOIUrl":"10.21037/tbcr-25-18","url":null,"abstract":"<p><strong>Background: </strong>Lymph node metastasis is an important predictive factor for the prognosis of breast cancer. Bone morphogenetic protein (BMP) and hepatocyte growth factor (HGF), and its receptor MET, are involved in metastasis. However, their predictive potential in the prediction of lymph node metastasis from breast cancer has not been evaluated to date. The aim of this study is to evaluate the implication of HGF and BMPs in breast cancer lymphatic metastasis.</p><p><strong>Methods: </strong>The association between the ligands and receptors of BMP, the regulators of HGF, and the modulators of MET were detected in Cardiff clinical breast cancer cohort and The Cancer Genome Atlas (TCGA) breast cancer ribonucleic acid (RNA) sequencing database. Predictive model of HGF and BMPs for nodal metastasis was evaluated by binary logistic regression and receiver operating characteristic (ROC) curve.</p><p><strong>Results: </strong>BMP-2 expression was upregulated but BMP-7 and matriptase-2 expression were downregulated in patients with nodal metastases. MET, matriptase-1, BMP-15, HAI-1, and matriptase-2 were correlated with the lymphangiogenesis markers. Lymphatic metastasis was positively with MET, matriptase-1 and BMP-15 but was negatively with matriptase-2, BMP-3, and HAI-1. ROC curve analysis showed the six factors with nodal status had a significant area under the curve values (0.657, P=0.001). The integrated signature could effectively predict lymph nodes involvement (P=0.006, hazard ratio =2.929).</p><p><strong>Conclusions: </strong>The aberrant expression of HGF/MET and BMPs is related to lymphatic metastasis in breast cancer. Integrated expression level of MET/BMP-15/matriptase-1 and the inversed HAI-1/BMP-3/matriptase-2 establishes a predictive model for lymph node involvement.</p>","PeriodicalId":101427,"journal":{"name":"Translational breast cancer research : a journal focusing on translational research in breast cancer","volume":"6 ","pages":"33"},"PeriodicalIF":1.4,"publicationDate":"2025-10-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12593985/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145484418","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-10-24eCollection Date: 2025-01-01DOI: 10.21037/tbcr-25-43
Muharrem Oner, Kefah Mokbel
{"title":"Could circulating tumor cells explain why breast conservation improves survival despite higher locoregional recurrence?","authors":"Muharrem Oner, Kefah Mokbel","doi":"10.21037/tbcr-25-43","DOIUrl":"10.21037/tbcr-25-43","url":null,"abstract":"","PeriodicalId":101427,"journal":{"name":"Translational breast cancer research : a journal focusing on translational research in breast cancer","volume":"6 ","pages":"39"},"PeriodicalIF":1.4,"publicationDate":"2025-10-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12593988/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145484442","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-10-23eCollection Date: 2025-01-01DOI: 10.21037/tbcr-25-25
Hans-Christian Kolberg
{"title":"TARGIT-IORT in early breast cancer-real world evidence for a risk-adapted approach.","authors":"Hans-Christian Kolberg","doi":"10.21037/tbcr-25-25","DOIUrl":"10.21037/tbcr-25-25","url":null,"abstract":"","PeriodicalId":101427,"journal":{"name":"Translational breast cancer research : a journal focusing on translational research in breast cancer","volume":"6 ","pages":"38"},"PeriodicalIF":1.4,"publicationDate":"2025-10-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12593987/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145484467","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-10-17eCollection Date: 2025-01-01DOI: 10.21037/tbcr-25-19
Sarah Fennelly, Bhaumik Shah, Michael Issac, Giulia McCorkell
<p><strong>Background: </strong>Neoadjuvant endocrine therapy (NAET) can induce a reduction of Ki-67 in hormone receptor-positive breast cancer, predicting response to adjuvant endocrine therapy and potentially allowing patients to forego chemotherapy without increasing recurrence risk. However, Ki-67 interpretation is highly variable. Implementation requires careful multidisciplinary planning to mitigate the effects of Ki-67 variability on treatment eligibility. Feasibility and short-term oncological outcomes of implementation of short-course NAET were studied during a "window of opportunity" where it was adopted by several unit surgeons without formal pathway development. A concurrent qualitative study identified barriers to NAET from surgeons' perspectives and gained insight from pathologists about Ki-67's suitability as a response marker. This identified potential issues with implementing this treatment based on existing protocols, which rely heavily on Ki-67 interpretation. The aims of this study were to investigate the feasibility of implementing short course NAET on the basis of Ki-67 values on an <i>ad hoc</i> basis and to use our experience to make recommendations for optimal translation of this treatment from research to clinical practice.</p><p><strong>Methods: </strong>Eligible patients were identified from multidisciplinary meeting (MDM) agendas from May 2023 to May 2024. These patients were post-menopausal women with hormone receptor-positive, HER2-negative breast cancer who were eligible for surgery and who had a Ki-67 of greater than 10% on core biopsy. Patients were split into a group of patients who received the treatment and a group who did not. Outcomes were recorded including treating surgeon, Ki-67 index changes, NAET duration, and choice of adjuvant therapy. Surgeons and pathologists were interviewed and a qualitative analysis was done identifying key themes and limitations of the treatment and existing protocols.</p><p><strong>Results: </strong>During the study, 44 eligible patients were discussed at the MDM. Fifty-five percent received NAET. Of these, 72% exhibited a reduction in Ki-67 compared to 40% in the non-NAET group. A substantial reduction (from >10% to <10%) was observed in 44% of NAET patients. Forty-four percent of patient values reduced across a threshold value of 10% (quoted in the POETIC study as indicating response to NAET). Where a substantial reduction occurred, no patients were recommended for adjuvant chemotherapy. In the qualitative arm, there was no overlap in key themes between surgeons and pathologists, demonstrating that surgeons may underestimate the limitations of Ki-67 interpretation. Pathologists raised concerns around limitations of Ki-67 interpretation, reproducibility and lack of common protocols in different units. Surgeons noted some barriers to prescribing and uncertainty that the treatment confers a benefit in a short time period.</p><p><strong>Conclusions: </strong>This study demonstrat
{"title":"Patient outcomes and clinician perspectives following one year of <i>ad hoc</i> implementation of neoadjuvant endocrine therapy in early breast cancer.","authors":"Sarah Fennelly, Bhaumik Shah, Michael Issac, Giulia McCorkell","doi":"10.21037/tbcr-25-19","DOIUrl":"10.21037/tbcr-25-19","url":null,"abstract":"<p><strong>Background: </strong>Neoadjuvant endocrine therapy (NAET) can induce a reduction of Ki-67 in hormone receptor-positive breast cancer, predicting response to adjuvant endocrine therapy and potentially allowing patients to forego chemotherapy without increasing recurrence risk. However, Ki-67 interpretation is highly variable. Implementation requires careful multidisciplinary planning to mitigate the effects of Ki-67 variability on treatment eligibility. Feasibility and short-term oncological outcomes of implementation of short-course NAET were studied during a \"window of opportunity\" where it was adopted by several unit surgeons without formal pathway development. A concurrent qualitative study identified barriers to NAET from surgeons' perspectives and gained insight from pathologists about Ki-67's suitability as a response marker. This identified potential issues with implementing this treatment based on existing protocols, which rely heavily on Ki-67 interpretation. The aims of this study were to investigate the feasibility of implementing short course NAET on the basis of Ki-67 values on an <i>ad hoc</i> basis and to use our experience to make recommendations for optimal translation of this treatment from research to clinical practice.</p><p><strong>Methods: </strong>Eligible patients were identified from multidisciplinary meeting (MDM) agendas from May 2023 to May 2024. These patients were post-menopausal women with hormone receptor-positive, HER2-negative breast cancer who were eligible for surgery and who had a Ki-67 of greater than 10% on core biopsy. Patients were split into a group of patients who received the treatment and a group who did not. Outcomes were recorded including treating surgeon, Ki-67 index changes, NAET duration, and choice of adjuvant therapy. Surgeons and pathologists were interviewed and a qualitative analysis was done identifying key themes and limitations of the treatment and existing protocols.</p><p><strong>Results: </strong>During the study, 44 eligible patients were discussed at the MDM. Fifty-five percent received NAET. Of these, 72% exhibited a reduction in Ki-67 compared to 40% in the non-NAET group. A substantial reduction (from >10% to <10%) was observed in 44% of NAET patients. Forty-four percent of patient values reduced across a threshold value of 10% (quoted in the POETIC study as indicating response to NAET). Where a substantial reduction occurred, no patients were recommended for adjuvant chemotherapy. In the qualitative arm, there was no overlap in key themes between surgeons and pathologists, demonstrating that surgeons may underestimate the limitations of Ki-67 interpretation. Pathologists raised concerns around limitations of Ki-67 interpretation, reproducibility and lack of common protocols in different units. Surgeons noted some barriers to prescribing and uncertainty that the treatment confers a benefit in a short time period.</p><p><strong>Conclusions: </strong>This study demonstrat","PeriodicalId":101427,"journal":{"name":"Translational breast cancer research : a journal focusing on translational research in breast cancer","volume":"6 ","pages":"34"},"PeriodicalIF":1.4,"publicationDate":"2025-10-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12593990/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145484440","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Background: Breast cancer is the most common tumor among women worldwide, which human epidermal growth factor receptor 2 (HER2)-positive subtype accounts for approximately 15-20%. Although anti-HER2 agents have already diversified in recent years, a highly effective and more affordable treatment option is urgently needed. Inetetamab is a new antibody exhibiting efficacy in managing HER2-positive advanced breast cancer (ABC) through antibody-dependent cellular cytotoxicity (ADCC). Pyrotinib is a second-line treatment specifically targeting HER2. Given that pyrotinib could exhibit strong HER2 antagonism and synergize with monoclonal antibodies to boost ADCC effect, herein we investigated the effects and safety of first to third line of combined treatments utilizing inetetamab plus vinorelbine and pyrotinib in dealing with HER2-positive ABC.
Methods: This is a multicenter, retrospective, real-world study. During the period of July 2020 to October 2023, 76 participants at 17 centers with HER2-positive ABC received the triple regimen and were evaluated for progression-free survival (PFS), overall survival (OS), objective response rate (ORR), and clinical benefit rate (CBR). Data regarding treatment-associated adverse events (TAAEs) were also collected.
Results: The median age of the participants enrolled was 53 years. Among the participants, 53 (69.7%) were diagnosed to suffer from visceral metastases, while 35 (46.1%) possessed hormone receptor-positive lesions. The median PFS (mPFS) of the cohort was 10.03 months [95% confidence interval (CI): 6.80 to 13.27]. The ORR and CBR were respectively 61.8% (47/76) and 97.4% (74/76). The TAAE with highest incidence was diarrhea (77.6%). Grades III and IV TAAEs with highest incidences were leukopenia (19.7%), neutropenia (19.7%), and diarrhea (17.1%). No severe TAAEs were observed during the investigation.
Conclusions: The triple regimen of inetetamab plus pyrotinib and vinorelbine exhibited promising therapeutic effects and was tolerable for participants with HER2-positive ABC.
{"title":"Combined treatment of inetetamab plus pyrotinib and vinorelbine in managing advanced HER2-positive breast cancer patients (ILLUMINE): a multicenter, retrospective, real-world study.","authors":"Nan Jin, Min Tian, Mengyao Zha, Lijun Shi, Guifang Zhang, Hui Zhao, Jiao Yang, Xuelian Chen, Yongkui Lu, Guohui Han, Xiangdong Bai, Wanping Liang, Hengyu Zhang, Wei Li, Xiang Huang, Yongmei Yin","doi":"10.21037/tbcr-25-7","DOIUrl":"10.21037/tbcr-25-7","url":null,"abstract":"<p><strong>Background: </strong>Breast cancer is the most common tumor among women worldwide, which human epidermal growth factor receptor 2 (HER2)-positive subtype accounts for approximately 15-20%. Although anti-HER2 agents have already diversified in recent years, a highly effective and more affordable treatment option is urgently needed. Inetetamab is a new antibody exhibiting efficacy in managing HER2-positive advanced breast cancer (ABC) through antibody-dependent cellular cytotoxicity (ADCC). Pyrotinib is a second-line treatment specifically targeting HER2. Given that pyrotinib could exhibit strong HER2 antagonism and synergize with monoclonal antibodies to boost ADCC effect, herein we investigated the effects and safety of first to third line of combined treatments utilizing inetetamab plus vinorelbine and pyrotinib in dealing with HER2-positive ABC.</p><p><strong>Methods: </strong>This is a multicenter, retrospective, real-world study. During the period of July 2020 to October 2023, 76 participants at 17 centers with HER2-positive ABC received the triple regimen and were evaluated for progression-free survival (PFS), overall survival (OS), objective response rate (ORR), and clinical benefit rate (CBR). Data regarding treatment-associated adverse events (TAAEs) were also collected.</p><p><strong>Results: </strong>The median age of the participants enrolled was 53 years. Among the participants, 53 (69.7%) were diagnosed to suffer from visceral metastases, while 35 (46.1%) possessed hormone receptor-positive lesions. The median PFS (mPFS) of the cohort was 10.03 months [95% confidence interval (CI): 6.80 to 13.27]. The ORR and CBR were respectively 61.8% (47/76) and 97.4% (74/76). The TAAE with highest incidence was diarrhea (77.6%). Grades III and IV TAAEs with highest incidences were leukopenia (19.7%), neutropenia (19.7%), and diarrhea (17.1%). No severe TAAEs were observed during the investigation.</p><p><strong>Conclusions: </strong>The triple regimen of inetetamab plus pyrotinib and vinorelbine exhibited promising therapeutic effects and was tolerable for participants with HER2-positive ABC.</p>","PeriodicalId":101427,"journal":{"name":"Translational breast cancer research : a journal focusing on translational research in breast cancer","volume":"6 ","pages":"31"},"PeriodicalIF":1.4,"publicationDate":"2025-09-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12593989/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145484506","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-08-19eCollection Date: 2025-01-01DOI: 10.21037/tbcr-25-15
Muharrem Oner, Kefah Mokbel
{"title":"Axillary management in patients with sentinel lymph node micrometastases following neoadjuvant systemic therapy: a call for de-escalation.","authors":"Muharrem Oner, Kefah Mokbel","doi":"10.21037/tbcr-25-15","DOIUrl":"10.21037/tbcr-25-15","url":null,"abstract":"","PeriodicalId":101427,"journal":{"name":"Translational breast cancer research : a journal focusing on translational research in breast cancer","volume":"6 ","pages":"41"},"PeriodicalIF":1.4,"publicationDate":"2025-08-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12593984/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145484502","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-07-23eCollection Date: 2025-01-01DOI: 10.21037/tbcr-25-14
Jianli Zhao, Ziyue Zhou, Wei Zhang, Kai Chen
{"title":"Omitting sentinel lymph node biopsy in early breast cancer: too bold or the future?","authors":"Jianli Zhao, Ziyue Zhou, Wei Zhang, Kai Chen","doi":"10.21037/tbcr-25-14","DOIUrl":"10.21037/tbcr-25-14","url":null,"abstract":"","PeriodicalId":101427,"journal":{"name":"Translational breast cancer research : a journal focusing on translational research in breast cancer","volume":"6 ","pages":"27"},"PeriodicalIF":1.4,"publicationDate":"2025-07-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12314679/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144777544","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-07-23eCollection Date: 2025-01-01DOI: 10.21037/tbcr-25-32
Li Bian, Shaohua Zhang, Man Li, Jin Yang, Yongmei Yin
{"title":"Precise targeting cytotoxicity of antibody-drug conjugate combined with immunotherapy as first-line regimen for metastatic triple-negative breast cancer in ASCENT-04.","authors":"Li Bian, Shaohua Zhang, Man Li, Jin Yang, Yongmei Yin","doi":"10.21037/tbcr-25-32","DOIUrl":"10.21037/tbcr-25-32","url":null,"abstract":"","PeriodicalId":101427,"journal":{"name":"Translational breast cancer research : a journal focusing on translational research in breast cancer","volume":"6 ","pages":"29"},"PeriodicalIF":1.4,"publicationDate":"2025-07-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12314681/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144777545","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"DESTINY-Breast09, new breakthroughs in first-line therapy for HER2-positive advanced breast cancer.","authors":"Jianbing Li, Chunfang Hao, Haibo Wang, Yueyin Pan, Zefei Jiang","doi":"10.21037/tbcr-25-35","DOIUrl":"10.21037/tbcr-25-35","url":null,"abstract":"","PeriodicalId":101427,"journal":{"name":"Translational breast cancer research : a journal focusing on translational research in breast cancer","volume":"6 ","pages":"28"},"PeriodicalIF":1.4,"publicationDate":"2025-07-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12314678/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144777540","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
扫码关注我们
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号